Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010 - Abstract

International Health Management Associates, Inc., Schaumburg, IL, USA.

 

Escherichia coli is the most important uropathogen. The Study for Monitoring Antimicrobial Resistance Trends program collected 1643 E. coli isolates in 2009-2010 from urinary tract infection (UTI) specimens of hospitalized patients in countries worldwide. Ertapenem and imipenem were the most active agents tested, inhibiting >98% of all E. coli phenotypes. Overall, 17.9% of isolates were extended-spectrum beta-lactamase (ESBL) producers. The highest ESBL rate was from the Asia/Pacific region (27.7%). Amikacin and piperacillin-tazobactam achieved 90% inhibition levels only for ESBL-negative isolates. Ciprofloxacin and levofloxacin were not effective for ESBL-positive isolates, with only 14.6% and 15.9% susceptible, respectively. These observations highlight the need for continued monitoring of susceptibility of E. coli isolated from hospitalized patients with UTIs.

Written by:
Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R.   Are you the author?

Reference: Diagn Microbiol Infect Dis. 2011 Aug;70(4):507-11.
doi: 10.1016/j.diagmicrobio.2011.03.021

PubMed Abstract
PMID: 21767706

UroToday.com Infections Section

 

 

email news signup